Dihematoporphyrin Ether FDA Link

The purified component of HEMATOPORPHYRIN DERIVATIVE, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (HEMATOPORPHYRIN PHOTORADIATION); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of PHOTODYNAMIC THERAPY in the United States.

Also Known As:

Porfimer Sodium; Photofrin; Dihematoporphyrin Ester; Photofrin II; Ether, Dihematoporphyrin; DHP Ether; Porfimer; 21H,23H-Porphine-2,18-dipropanoic acid, 7- (1- (1- (8,12- bis(2- carboxyethyl)- 17- (1- hydroxyethyl)- 3,7,13,18- tetramethyl- 21H,23H- porphin- 2- yl)ethoxy)ethyl)- 12- (1- hydroxyethyl)- 3,8,13,17- tetramethyl-

Pharmalogical Action Categories:

Antineoplastic Agents
Dermatologic Agents
Photosensitizing Agents

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - Tetrapyrroles: 70
        Porphyrins: 3316
        Hematoporphyrins: 324
        Hematoporphyrin Derivative: 536
        Dihematoporphyrin Ether: 718
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Tetrapyrroles: 70
      - Porphyrins: 3316
        Hematoporphyrins: 324
        Hematoporphyrin Derivative: 536
        Dihematoporphyrin Ether: 718
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Tetrapyrroles: 70
    - Porphyrins: 3316
      - Hematoporphyrins: 324
        Hematoporphyrin Derivative: 536
        Dihematoporphyrin Ether: 718
Biological Factors: 2472
- Biological Pigments: 1
  - Porphyrins: 3316
    - Hematoporphyrins: 324
      - Hematoporphyrin Derivative: 536
        Dihematoporphyrin Ether: 718

M L de Jode Selected Research

M L de Jode Research Topics

Disease

Drug/Important Bio-Agent (IBA)